Literature DB >> 33977468

Ras Variant Biology and Contributions to Human Disease.

Ian Prior1.   

Abstract

Analysis of cancer and RASopathy genetic databases reveals that ~19% of all cancer cases and ~4% of developmental disorders contain Ras mutations. Ras isoform and mutation variants differentially contribute to these diseases and provide an opportunity for deeper understanding of Ras function. The putative mechanisms underpinning these differences, new approaches that are being applied, and some of the key questions and challenges that remain are discussed.

Entities:  

Keywords:  COSMIC; Cancer; HRAS; KRAS; NRAS; RASopathy; TCGA

Year:  2021        PMID: 33977468     DOI: 10.1007/978-1-0716-1190-6_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  48 in total

1.  Formation of the Ras dimer is essential for Raf-1 activation.

Authors:  K Inouye; S Mizutani; H Koide; Y Kaziro
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

2.  Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf.

Authors:  T Okada; T Masuda; M Shinkai; K Kariya; T Kataoka
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

Review 3.  RAS isoforms and mutations in cancer at a glance.

Authors:  G Aaron Hobbs; Channing J Der; Kent L Rossman
Journal:  J Cell Sci       Date:  2016-03-16       Impact factor: 5.285

Review 4.  Ras nanoclusters: Versatile lipid-based signaling platforms.

Authors:  Yong Zhou; John F Hancock
Journal:  Biochim Biophys Acta       Date:  2014-09-16

5.  K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions.

Authors:  Jean K Chung; Young Kwang Lee; John-Paul Denson; William K Gillette; Steven Alvarez; Andrew G Stephen; Jay T Groves
Journal:  Biophys J       Date:  2018-01-09       Impact factor: 4.033

6.  Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction.

Authors:  Kerry L Inder; Chiyan Lau; Dorothy Loo; Natasha Chaudhary; Andrew Goodall; Sally Martin; Alun Jones; Dharini van der Hoeven; Robert G Parton; Michelle M Hill; John F Hancock
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

7.  RASSF6 is a novel member of the RASSF family of tumor suppressors.

Authors:  N P C Allen; H Donninger; M D Vos; K Eckfeld; L Hesson; L Gordon; M J Birrer; F Latif; G J Clark
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

8.  Inhibition of RAS function through targeting an allosteric regulatory site.

Authors:  Russell Spencer-Smith; Akiko Koide; Yong Zhou; Raphael R Eguchi; Fern Sha; Priyanka Gajwani; Dianicha Santana; Ankit Gupta; Miranda Jacobs; Erika Herrero-Garcia; Jacqueline Cobbert; Hugo Lavoie; Matthew Smith; Thanashan Rajakulendran; Evan Dowdell; Mustafa Nazir Okur; Irina Dementieva; Frank Sicheri; Marc Therrien; John F Hancock; Mitsuhiko Ikura; Shohei Koide; John P O'Bryan
Journal:  Nat Chem Biol       Date:  2016-11-07       Impact factor: 15.040

9.  KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Authors:  Chiara Ambrogio; Jens Köhler; Zhi-Wei Zhou; Haiyun Wang; Raymond Paranal; Jiaqi Li; Marzia Capelletti; Cristina Caffarra; Shuai Li; Qi Lv; Sudershan Gondi; John C Hunter; Jia Lu; Roberto Chiarle; David Santamaría; Kenneth D Westover; Pasi A Jänne
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

10.  The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.

Authors:  Hossein Nakhaeizadeh; Ehsan Amin; Saeideh Nakhaei-Rad; Radovan Dvorsky; Mohammad Reza Ahmadian
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

View more
  2 in total

Review 1.  Neurodevelopmental disorders, immunity, and cancer are connected.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  iScience       Date:  2022-05-30

2.  How can same-gene mutations promote both cancer and developmental disorders?

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Sci Adv       Date:  2022-01-14       Impact factor: 14.136

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.